Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure

Norimichi Koitabashi, Masashi Arai, Kazuo Niwano, Atai Watanabe, Michiko Endoh, Masahiko Suguta, Tomoyuki Yokoyama, Hiroshi Tada, Takuji Toyama, Hitoshi Adachi, Shigeto Naito, Shigeru Oshima, Takashi Nishida, Satoshi Kubota, Masaharu Takigawa, Masahiko Kurabayashi

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. Methods and results: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r = 0.395, P <0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-β) (r = 0.512, P <0.01), matrix metalloproteinase (MMP)-2 (r = 0.391, P <0.05) and tissue inhibitor of MMP (TIMP)-2 (r = 0.354, P <0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r = 0.593, P = 0.012), but not with systolic function and left ventricular mass. Conclusion: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.

Original languageEnglish
Pages (from-to)373-379
Number of pages7
JournalEuropean Journal of Heart Failure
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Connective Tissue Growth Factor
Heart Failure
Biomarkers
Fibrosis
Matrix Metalloproteinase 2
Tissue Inhibitor of Metalloproteinase-2
Doppler Echocardiography
Brain Natriuretic Peptide
Left Ventricular Function
Transforming Growth Factor beta

Keywords

  • Cytokines
  • Extracellular matrix
  • Natriuretic peptide
  • Ventricular remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. / Koitabashi, Norimichi; Arai, Masashi; Niwano, Kazuo; Watanabe, Atai; Endoh, Michiko; Suguta, Masahiko; Yokoyama, Tomoyuki; Tada, Hiroshi; Toyama, Takuji; Adachi, Hitoshi; Naito, Shigeto; Oshima, Shigeru; Nishida, Takashi; Kubota, Satoshi; Takigawa, Masaharu; Kurabayashi, Masahiko.

In: European Journal of Heart Failure, Vol. 10, No. 4, 04.2008, p. 373-379.

Research output: Contribution to journalArticle

Koitabashi, N, Arai, M, Niwano, K, Watanabe, A, Endoh, M, Suguta, M, Yokoyama, T, Tada, H, Toyama, T, Adachi, H, Naito, S, Oshima, S, Nishida, T, Kubota, S, Takigawa, M & Kurabayashi, M 2008, 'Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure', European Journal of Heart Failure, vol. 10, no. 4, pp. 373-379. https://doi.org/10.1016/j.ejheart.2008.02.011
Koitabashi, Norimichi ; Arai, Masashi ; Niwano, Kazuo ; Watanabe, Atai ; Endoh, Michiko ; Suguta, Masahiko ; Yokoyama, Tomoyuki ; Tada, Hiroshi ; Toyama, Takuji ; Adachi, Hitoshi ; Naito, Shigeto ; Oshima, Shigeru ; Nishida, Takashi ; Kubota, Satoshi ; Takigawa, Masaharu ; Kurabayashi, Masahiko. / Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. In: European Journal of Heart Failure. 2008 ; Vol. 10, No. 4. pp. 373-379.
@article{1b2d798db0ba4bbfb3729a632fa69fe3,
title = "Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure",
abstract = "Background: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. Methods and results: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r = 0.395, P <0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-β) (r = 0.512, P <0.01), matrix metalloproteinase (MMP)-2 (r = 0.391, P <0.05) and tissue inhibitor of MMP (TIMP)-2 (r = 0.354, P <0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r = 0.593, P = 0.012), but not with systolic function and left ventricular mass. Conclusion: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.",
keywords = "Cytokines, Extracellular matrix, Natriuretic peptide, Ventricular remodeling",
author = "Norimichi Koitabashi and Masashi Arai and Kazuo Niwano and Atai Watanabe and Michiko Endoh and Masahiko Suguta and Tomoyuki Yokoyama and Hiroshi Tada and Takuji Toyama and Hitoshi Adachi and Shigeto Naito and Shigeru Oshima and Takashi Nishida and Satoshi Kubota and Masaharu Takigawa and Masahiko Kurabayashi",
year = "2008",
month = "4",
doi = "10.1016/j.ejheart.2008.02.011",
language = "English",
volume = "10",
pages = "373--379",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure

AU - Koitabashi, Norimichi

AU - Arai, Masashi

AU - Niwano, Kazuo

AU - Watanabe, Atai

AU - Endoh, Michiko

AU - Suguta, Masahiko

AU - Yokoyama, Tomoyuki

AU - Tada, Hiroshi

AU - Toyama, Takuji

AU - Adachi, Hitoshi

AU - Naito, Shigeto

AU - Oshima, Shigeru

AU - Nishida, Takashi

AU - Kubota, Satoshi

AU - Takigawa, Masaharu

AU - Kurabayashi, Masahiko

PY - 2008/4

Y1 - 2008/4

N2 - Background: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. Methods and results: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r = 0.395, P <0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-β) (r = 0.512, P <0.01), matrix metalloproteinase (MMP)-2 (r = 0.391, P <0.05) and tissue inhibitor of MMP (TIMP)-2 (r = 0.354, P <0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r = 0.593, P = 0.012), but not with systolic function and left ventricular mass. Conclusion: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.

AB - Background: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. Methods and results: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r = 0.395, P <0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-β) (r = 0.512, P <0.01), matrix metalloproteinase (MMP)-2 (r = 0.391, P <0.05) and tissue inhibitor of MMP (TIMP)-2 (r = 0.354, P <0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r = 0.593, P = 0.012), but not with systolic function and left ventricular mass. Conclusion: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.

KW - Cytokines

KW - Extracellular matrix

KW - Natriuretic peptide

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=41449097556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41449097556&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2008.02.011

DO - 10.1016/j.ejheart.2008.02.011

M3 - Article

VL - 10

SP - 373

EP - 379

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 4

ER -